PRTC Stock Analysis: Buy, Sell, or Hold?
PRTC - PureTech Health plc American Depositary Shares
$15.52
0.52 (3.47%)
▲
5d:
-1.46%
30d:
-10.03%
90d:
-9.61%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: Apr 30, 2026
23d
Get Alerted When PRTC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PRTC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: PRTC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PRTC is currently trading at $15.52, which is considered slightly low relative to its 30-day fair value range of $15.47 to $17.09.
Technical Outlook: Technically, PRTC is showing sideways momentum. Immediate support is located at $14.50, while resistance sits at $16.25. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: PRTC has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $46.00 (+196.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PRTC is showing sideways momentum. Immediate support is located at $14.50, while resistance sits at $16.25. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: PRTC has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $46.00 (+196.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$15.47 -
$17.09
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 196.4% below Wall St target ($46.00)
Fair Price Analysis
30-Day Fair Range
$15.47 -
$17.09
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$14.50
Resistance Level
$16.25
Current Trend
Sideways
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.75
Wall Street Target
$46.00
(+196.4%)
Revenue Growth (YoY)
542.7%
Earnings Growth (YoY)
61.5%
Profit Margin
793.0%
Share & Embed Analysis
Last updated: April 06, 2026 2:14 AM ET
Data refreshes hourly during market hours. Next update: 3:14 AM
Data refreshes hourly during market hours. Next update: 3:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRTC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 65 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 57 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 61 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 50 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 61 BUY |
